Taysha
Apr 13, 2021
Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities
Taysha takes charge of a Rare Disease Gene Therapy for $5.5 M Taysha Gene Therapies announced the acquisition of exclusive global rights to TSHA-120 from a leading patient advocacy group for an upfront payment of USD 5.5 million. TSHA-120 is an intrathecally dosed AAV9 gene therapy designed to tre...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
